H.R. 1499, Protecting Consumer Access to Generic Drugs Act of 2019 - Provisions related to patent settlements
H.R. 1503, Orange Book Transparency Act of 2019 - Provisions related to patent listings
H.R. 1506, Fair and Immediate Release of (FAIR) Generic Drugs Act - Provisions related to 180 day exclusivity and patent litigation
H.R. 1520, Purple Book Continuity Act of 2019 - Provisions related to biologics patent listings
S. 659, Biologic Patent Transparency Act - Provisions related to biologic patent disclosures
S. 1224, Stop STALLING Act - Provisions related to citizen petitions
S. 1416, Affordable Prescriptions for Patients Act of 2019 - Provisions related to prescription drug patents
Biopharmaceutical innovation and patent policy issues
Patent litigation reform issues and issues related to post-grant proceeding at the PTO
Value of intellectual property 
Patent protection H.R. 1506, Fair and Immediate Release of (FAIR) Generic Drugs Act - Provisions related to generic prescription drug approvals
H.R. 2113, Prescription Drug STAR Act - Provisions related to transparency of prescription drug pricing
S. 474, Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act of 2019 -Provisions related to wholesale acquisition costs of prescription drugs
S.1895, Lower Health Care Costs Act - Provisions related to prescription drug pricing, transparency and patent issues
340B drug discount program policy issues
Drug cost and pricing policy issues
Transparency policy issues H.R. 107, To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs - Provisions related to Medicaid rebates
H.R. 1046, Medicare Negotiation and Competitive Licensing Act of 2019 - Provisions related to Part D, drug pricing negotiation and march-in rights
S. 475, RxCAP Act of 2019 - Provisions related to Part D and patient cost-sharing
Department of Health and Human Services (HHS) drug policy issues and regulatory policy issues
Part D policy issues including non-interference, out of pocket cap and rebates policy issues
Medicaid policy issues including rebates policy and average manufacture price (AMP) caps
CMS Advanced Notice of Proposed Rulemaking on International Pricing Index Model for Medicare Part B Drugs
CMS Proposed Rulemaking to Require Manufacturers to Disclose Drug Prices in Television Ads
Proposed Rule: Modernizing Part D and Medicare Advantage to Lower Drug Prices and Reduce Out-of-Pocket Expenses, CMS 4180-P
Proposed Rule: OIG-0936-P Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees H.R. 2740, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Bill 2020 - HHS provisions related to prescription drugs Trade Agreements including NAFTA, USMCA and related policy issues Public Law 115-97 (formerly known as H.R. 1, Tax Cuts and Jobs Act) Implementation to provide for reconciliation pursuant to titles II and V of the concurrent resolution on the budget for fiscal year 2018 
Draft legislation relating to economic activity in Puerto Rico
CPT - Copyright/Patent/Trademark HCR - Health Issues MMM - Medicare/Medicaid BUD - Budget/Appropriations TRD - Trade (domestic/foreign) TAX - Taxation/Internal Revenue Code
14 - Council of Economic Advisers (CEA) 34 - Health & Human Services, Dept of (HHS) 2 - HOUSE OF REPRESENTATIVES 1 - SENATE 10 - Vice President of the U.S. 14 - Council of Economic Advisers (CEA) 34 - Health & Human Services, Dept of (HHS) 2 - HOUSE OF REPRESENTATIVES 1 - SENATE 10 - Vice President of the U.S. 14 - Council of Economic Advisers (CEA) 34 - Health & Human Services, Dept of (HHS) 2 - HOUSE OF REPRESENTATIVES 1 - SENATE 10 - Vice President of the U.S. 14 - Council of Economic Advisers (CEA) 34 - Health & Human Services, Dept of (HHS) 2 - HOUSE OF REPRESENTATIVES 1 - SENATE 10 - Vice President of the U.S. 14 - Council of Economic Advisers (CEA) 34 - Health & Human Services, Dept of (HHS) 2 - HOUSE OF REPRESENTATIVES 1 - SENATE 10 - Vice President of the U.S. 14 - Council of Economic Advisers (CEA) 34 - Health & Human Services, Dept of (HHS) 2 - HOUSE OF REPRESENTATIVES 1 - SENATE 10 - Vice President of the U.S.
ABBVIE, INC.
1399 New York Avenue NW, Suite 600, Washington, DC, 20005, US
DANIEL BACHNER STEPHEN SCANGO COURTNEY PIRON BINTA BEARD STEPHEN SCANGO DANIEL BACHNER COURTNEY PIRON HAYDEN RHUDY KENNEDY BINTA BEARD STEPHEN SCANGO DANIEL BACHNER COURTNEY PIRON HAYDEN RHUDY KENNEDY BINTA BEARD BINTA BEARD DANIEL BACHNER STEPHEN SCANGO COURTNEY PIRON DANIEL BACHNER COURTNEY PIRON STEPHEN SCANGO DANIEL BACHNER STEPHEN SCANGO COURTNEY PIRON